Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Chemocentryx
Thumbnail
August 04, 2022

Amgen picks its moment to strike for Chemocentryx

The $3.7bn price is cheaper than it would have been last year, but Tavneos must still fulfill its pipeline-in-a-product potential.

Thumbnail
November 22, 2021

Vifor plumps for a double acquisition

Article image
Vantage logo
November 01, 2021

US FDA approval tracker: October 2021

Article image
Vantage logo
October 08, 2021

FDA seals Chemocentryx’s fate

Article image
Vantage logo
October 01, 2021

Go or no go? UCB bids to make a mark in psoriasis

Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.

Article image
Vantage logo
August 02, 2021

US FDA approval tracker: July 2021

Article image
Vantage logo
July 09, 2021

Alzheimer’s and Covid-19 developers make hay on the stock markets

Big risers include Eli Lilly, Biogen, Moderna and Biontech.

Article image
Vantage logo
July 07, 2021

US regulator throws Chemocentryx a debatable lifeline

Article image
Vantage logo
June 30, 2021

Go or no go? Ardelyx and Chemocentryx among those waiting FDA decisions

Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.

Article image
Vantage logo
June 17, 2021

The big approvals still on the cards for 2021

Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.

Article image
Vantage logo
June 02, 2021

US FDA approval tracker: May 2021

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 12, 2022

Q2 Roundup Infographic

August 10, 2022

Q2 Roundup eBook

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.